Curis Inc. Files 8-K: Other Events & Financials Reported

Ticker: CRIS · Form: 8-K · Filed: Aug 8, 2025 · CIK: 1108205

Curis INC 8-K Filing Summary
FieldDetail
CompanyCuris INC (CRIS)
Form Type8-K
Filed DateAug 8, 2025
Risk Levelmedium
Pages2
Reading Time3 min
Key Dollar Amounts$0.01, $8,137,047, $100.0 million
Sentimentneutral

Sentiment: neutral

Topics: 8-K, regulatory-filing, financials

TL;DR

Curis filed an 8-K on 8/8/25 for other events and financials - details TBD.

AI Summary

Curis, Inc. filed an 8-K on August 8, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not contain specific details about the nature of these events or financial statements, only the reporting of their existence.

Why It Matters

This 8-K filing indicates that Curis, Inc. has reported significant events and financial information, which could impact investors' understanding of the company's current status.

Risk Assessment

Risk Level: medium — The filing is an 8-K, which typically reports material events, but the lack of specific details in this filing makes it difficult to assess the immediate impact or risk.

Key Numbers

Key Players & Entities

FAQ

What specific 'Other Events' are being reported by Curis, Inc. in this 8-K filing?

The filing does not specify the nature of the 'Other Events' beyond listing it as an item of information.

What are the key details of the 'Financial Statements and Exhibits' mentioned in the 8-K?

The filing lists 'Financial Statements and Exhibits' as reported items but does not provide any specific details or summaries of these documents.

When was this 8-K filing submitted to the SEC?

The filing was submitted on August 8, 2025.

Where are Curis, Inc.'s principal executive offices located?

Curis, Inc.'s principal executive offices are located at 128 Spring Street, Building C - Suite 500, Lexington, MA 02421.

What is the SIC code for Curis, Inc. as listed in the filing?

The Standard Industrial Classification (SIC) code listed for Curis, Inc. is 2836, which corresponds to 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)'.

Filing Stats: 712 words · 3 min read · ~2 pages · Grade level 11.4 · Accepted 2025-08-08 17:29:12

Key Financial Figures

Filing Documents

01. Other Events

Item 8.01. Other Events. On August 8, 2025, Curis, Inc. (the "Company") filed a prospectus supplement (the "Prospectus Supplement") under the Company's universal shelf registration statement on Form S-3 (File No. 333-276950) that was originally filed with the Securities and Exchange Commission (the "SEC") on February 8, 2024 and was declared effective by the SEC on April 12, 2024 (the "Registration Statement"), relating to the offer and sale of a total of up to $8,137,047 of shares of the Company's common stock, par value $0.01 per share (the "Shares"), pursuant to an Amended and Restated Sales Agreement, dated February 8, 2024, between the Company and Cantor Fitzgerald & Co. ("Cantor") and JonesTrading Institutional Services LLC ("Jones"), as agents (the "Sales Agreement"). As previously disclosed, on July 1, 2025, the Company notified Cantor and Jones that it was terminating a prior prospectus filed with the SEC on February 8, 2024 and dated April 12, 2024 related to the offer and sale of shares of the Company's common stock having an aggregate offering price of up to $100.0 million pursuant to the Sales Agreement. The Sales Agreement remained in full force and effect. Wilmer Cutler Pickering Hale and Dorr LLP, counsel to the Company, has issued a legal opinion relating to the Shares. A copy of such legal opinion, including the consent included therein, is attached as Exhibit 5.1 hereto. The Shares are registered pursuant to the Registration Statement and the base prospectus contained therein, and offerings for the Shares will be made only by means of the Prospectus Supplement. This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. Exhibit Number Description 5.1 Opinion of Wilmer Cutler Pickering Hale and Dorr LLP 23.1 Consent of Wilmer Cutler Pickering Hale and Dorr LLP (contained in Exhibit 5.1 above) 104 Cover Page Interactive Data File (embedded within the InLine XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Curis, Inc. Date: August 8, 2025 By: /s/ Diantha Duvall Diantha Duvall Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing